Rosen Law Firm’s probe into Tandem Diabetes Care (TNDM) after a voluntary correction of certain t:slim X2 insulin pumps, and the roughly 20% share drop that followed, has investors reassessing risk ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has ...
The AID system used in the study is knowns as a Tandem t:slim X2 insulin pump with Control-IQ technology. "We've known for a while that AID systems have achieved better glucose control with less ...
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from ...
Medical Device Network on MSN
FDA clears Android version of Tandem Mobi mobile application
The US Food and Drug Administration (FDA) has granted clearance for the Android version of Tandem Diabetes Care’s Tandem Mobi ...
Submission delayed by U.S. government shutdown; initial FDA questions expected during Q4 2025 "The Pivot submission is an exciting milestone in our mission to deliver a differentiated tubeless patch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback